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Dietary fat stimulates development 
of NAFLD more potently than dietary fructose 
in Sprague–Dawley rats
Victoria Svop Jensen1,2*, Henning Hvid2, Jesper Damgaard2, Helle Nygaard2, Camilla Ingvorsen3, 
Erik Max Wulff4, Jens Lykkesfeldt1 and Christian Fledelius2
Abstract 
Background: In humans and animal models, excessive intake of dietary fat, fructose and cholesterol has been linked 
to the development of non-alcoholic fatty liver disease (NAFLD). However, the individual roles of the dietary compo-
nents remain unclear. To investigate this further, we compared the effects of a high-fat diet, a high-fructose diet and a 
combination diet with added cholesterol on the development of NAFLD in rats.
Methods: Forty male Sprague–Dawley rats were randomized into four groups receiving either a control-diet (Con-
trol: 10% fat); a high-fat diet (HFD: 60% fat, 20% carbohydrate), a high-fructose diet [HFr: 10% fat, 70% carbohydrate 
(mainly fructose)] or a high-fat/high-fructose/high-cholesterol-diet (NASH: 40% fat, 40% carbohydrate (mainly fruc-
tose), 2% cholesterol) for 16 weeks.
Results: After 16 weeks, liver histology revealed extensive steatosis and inflammation in both NASH- and HFD-fed 
rats, while hepatic changes in HFr-rats were much more subtle. These findings were corroborated by significantly 
elevated hepatic triglyceride content in both NASH- (p < 0.01) and HFD-fed rats (p < 0.0001), elevated hepatic cho-
lesterol levels in NASH-fed rats (p < 0.0001), but no changes in HFr-fed rats, compared to Control. On the contrary, 
only HFr-fed rats developed dyslipidemia as characterized by higher levels of plasma triglycerides compared to all 
other groups (p < 0.0001). Hepatic dysfunction and inflammation was confirmed in HFD-fed rats by elevated levels of 
hepatic MCP-1 (p < 0.0001), TNF-alpha (p < 0.001) and plasma β-hydroxybutyrate (p < 0.0001), and in NASH-fed rats by 
elevated levels of hepatic MCP-1 (p < 0.01), increased hepatic macrophage infiltration (p < 0.001), and higher plasma 
levels of alanine aminotransferase (p < 0.0001) aspartate aminotransferase (p < 0.05), haptoglobin (p < 0.001) and 
TIMP-1 (p < 0.01) compared to Control.
Conclusion: These findings show that dietary fat and cholesterol are the primary drivers of NAFLD development and 
progression in rats, while fructose mostly exerts its effect on the circulating lipid pool.
Keywords: Non-alcoholic fatty liver disease, NAFLD, Animal models, Diet, Fat, Fructose, Cholesterol, Non-alcoholic 
steatohepatitis, NASH, Rat
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Background
Non-alcoholic fatty liver disease (NAFLD) constitutes an 
increasingly prevalent liver disorder and has been sug-
gested to be the hepatic manifestation of the metabolic 
syndrome [1]. At present, NAFLD is assuming epidemic 
proportions affecting more than 25% of the world’s popu-
lation, likely related to a concurrent rise in the prevalence 
of obesity and type 2 diabetes [2], although an increasing 
proportion of normal weight individuals are also affected 
pointing towards dyslipidemia as an important independ-
ent risk factor [3]. NAFLD denotes a broad range of liver 
pathologies, spanning from simple hepatic steatosis, to 
advanced non-alcoholic steatohepatitis (NASH), which 
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without intervention may progress to transplant-requir-
ing cirrhosis and hepatocellular carcinoma. Whereas 
simple hepatic steatosis is mainly characterized by lipid 
accumulation in > 5% of hepatocytes, NASH is a condi-
tion further complicated by lobular inflammatory infil-
trations and the presence of ballooning hepatocytes with 
or without concurrent fibrosis [4].
It has been hypothesized that progression through 
NAFLD stages involves multiple adverse “hits” where 
both hepatic inflammation and oxidative stress are key 
facilitators [5]. Accordingly, serum and hepatic levels of 
proinflammatory cytokines such as tumor-necrosis factor 
alpha (TNF-α) and monocyte-chemoattractant protein-1 
(MCP-1) have been found to be increased in patients 
with both simple hepatic steatosis and NASH [6–9]. 
Also, the glycoproteins haptoglobin and tissue-inhibitor 
of metalloproteinase 1 (TIMP-1) have been shown to be 
elevated in plasma of patients with more advanced stages 
of NAFLD and have therefore recently been suggested as 
useful clinical plasma biomarkers, indicative of hepato-
cyte ballooning and liver fibrosis, respectively [10, 11].
Even though the specific etiology of NAFLD remains 
unclear, dietary fat and cholesterol have been linked to 
the development of hepatic steatosis and NASH in both 
humans and animal models [12–14] and more recently, 
the marked increase in consumption of the simple car-
bohydrate fructose, has been pointed out as another pos-
sible contributory factor [15, 16]. The realization that 
diet is an important contributor to the pathogenesis of 
NAFLD has resulted in a considerable variety of diet-
induced animal models, where the majority (apart from 
those based on nutritional deficiencies) is based on a 
high-fat diet with varying levels of simple carbohydrate 
and cholesterol [17, 18]. However, the individual roles of 
fat, carbohydrates and cholesterol in the development of 
NAFLD are still not entirely clear. Thus, improved insight 
from animal studies on the individual contribution of fat, 
simple carbohydrates and cholesterol to the metabolic 
and inflammatory characteristics of NAFLD is an impor-
tant prerequisite in understanding the disease complexity 
in patients. Furthermore, establishment of animal models 
of NAFLD/NASH that more adequately mimic human 
pathology will be valuable when testing novel therapeu-
tics for NAFLD/NASH.
The aim of the present study was therefore to compare 
the effects of diets high in either dietary fat, dietary fruc-
tose or a combination diet with added cholesterol on devel-
opment of NAFLD, dyslipidemia and inflammation in 
Sprague–Dawley rats. Development of NAFLD was evalu-
ated over time both histologically and biochemically and 
quantitative computed tomography (qCT) was used as a 
non-invasive marker of hepatic steatosis, enabling monitor-
ing of NAFLD progression throughout the study period.
Methods
Animals
Forty male Sprague–Dawley rats were purchased from 
Charles River Laboratories (Sulzfeld, Germany). Ani-
mals were acclimatized for 2 weeks upon arrival and were 
12 weeks old at the beginning of the experiment, weigh-
ing approximately 440–460 g. They were housed two per 
cage with access to non-chlorinated, non-acidific tap-
water and with unrestricted access to standard rodent 
chow (Altromin 1324, Brogaarden, Denmark) until initia-
tion of the experiment. Temperature in the animal rooms 
was maintained at 20–25  °C with a light/dark cycle of 
12/12  h, a relative humidity of 30–70%, and air change 
8–15 times/h.
Experimental design
Immediately prior to study start, rats were block-ran-
domized into four diet groups based on body weight 
(n  =  10/group). Briefly, rats were sorted in order of 
ascending weight into blocks, and within each block, rats 
were then randomly assigned to receive either a control 
diet (Control), a high-fat diet (HFD), a high-fructose diet 
(HFr) or a high-fat/high-fructose/high-cholesterol-diet 
(NASH), (Research Diets, NJ, USA) for 16  weeks. The 
length of the study period was chosen to enhance the 
probability that NASH with concurrent fibrosis would 
be established, as has previously been described in 
Sprague–Dawley rats fed a high-fat diet [19]. The exact 
nutritional composition of each diet is shown in Table 1. 
All diets were stored at −  20  °C throughout the study 
until use, and feed-remains were exchanged with fresh 
feed twice weekly to prevent purification. To obtain base-
line values for all parameters assessed at the 16 week time 
point, animals were qCT-scanned, quantitative magnetic 
resonance (qMR)-scanned and blood sampled at study 
start. After 16 weeks, animals were euthanized by exsan-
guination under isoflurane anesthesia by incision of the 
abdominal aorta. Immediately following exsanguination, 
Table 1 Nutritional composition of diets
NASH NASH-diet, HFD high-fat diet, HFr high-fructose diet
Nutrient composition Control NASH HFD HFr
Fat (%) 10 40 60 10
Carbohydrates (total) (%) 70 40 20 70
 Fructose (%) 0 20 0 60
 Sucrose (%) 0 10 7 1
 Corn starch (%) 55 0 0 9
 Maltodextrin 10 (%) 15 10 13 0
Protein (%) 20 20 20 20
Cholesterol (%) – 2 – –
Metabolizable energy (kcal/g) 3.85 4.49 5.24 3.85
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the liver, a 5 cm section of the proximal jejunum and the 
two epididymal fat depots were excised, weighed and 
freeze clamped for further analysis. Food intake and body 
weight was measured twice weekly throughout the study. 
Food intake was recorded by calculating the difference 
between the amount of administered food and remain-
ing food in the cage. These data were used to calculate 
the accumulated energy intake after the 16 weeks. qCT- 
and qMR-scans was performed on a bi-monthly basis, 
and blood samples were collected at baseline and at study 
termination.
Plasma samples
Blood samples were taken from the sublingual vein in 
conscious non-fasted animals. They were collected 
in  K3-EDTA microvettes and after centrifugation 
plasma was isolated and kept at −  20  °C until further 
analysis. Triglycerides (TG), total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL-C), free 
fatty acids (FFA), alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), Haptoglobin and 
β-hydroxybutyrate were measured using a Cobas 6000 
c501 instrument (Roche Diagnostics GmbH, D-68296 
Mannheim, Germany), according to manufacturer’s 
instructions. Plasma levels of MCP-1 and TIMP-1 were 
analyzed using a multiplex assay, (K15179-C1, Mes-
oscale Discovery, MD, USA).
Additionally, plasma samples were collected from 4-h 
fasted animals at week 15 (collected 1 week prior to week 
16 blood samples, to avoid the fasting interfering with 
plasma lipid parameters) and assayed for endogenous 
insulin and glucose. Samples for blood glucose meas-
urements (10  µL) were collected in capillary tubes and 
transferred to 500  µL system solution. Blood glucose 
levels were analyzed using the glucose oxidase method 
at a Biosen apparatus (EKF Diagnostics, Barleben, Ger-
many) according to manufacturer’s instructions. Samples 
for endogenous insulin measurements were collected in 
 K3-EDTA microvettes and after centrifugation; plasma 
was isolated and analyzed as previously described [20]. 
Leptin levels were quantified using a Milliplex assay 
(RADPKMAG80-K, Merck, Hellerup, DK).
qMR and qCT
To determine total fat mass, all animals underwent qMR-
scans after 8 and 16 weeks using an EchoMRI Body Com-
position Analyser (EchoMRI, Houston, TX, USA). Mass 
measurements of fat tissue were performed according to 
manufacturer’s instructions and as previously described 
[21].
In order to assess the development and progression 
of NAFLD, qCT scans were used to quantify liver den-
sity as an indirect measure of hepatic fat content. Liver 
qCT-scans were performed after 8 and 16 weeks in iso-
flurane-anesthetized rats using a Latheta CT-scanner 
(LCT-200 series, Aloka co. LTD, Tokyo, Japan). Changes 
in liver density were calculated by subtracting baseline 
qCT values from week 8 and 16 time point values.
Liver biochemistry
Levels of hepatic TG, TC and liver glycogen were ana-
lyzed on homogenized liver tissue sampled from the left 
lateral lobe using a Cobas 6000 c501 instrument (Roche 
Diagnostics GmbH 68206 Mannheim, Germany) accord-
ing to manufacturer’s instructions and as previously 
described [22].
Histology
The right medial, the left lateral, and the caudate lobe 
of the liver were collected for histological examination. 
Samples were fixed in 10% Neutral Buffered Formalin, 
processed to paraffin, imbedded and cut in 2–4 µm sec-
tions. In addition, a sample from the left medial lobe was 
snap frozen for cryo-sectioning. Steatosis was evaluated 
in all three lobes with Mayer’s Haematoxylin and Eosin 
(H&E) on paraffin section (10 animals/gr) and confirmed 
by Oil Red O-stain on frozen cryo-sections of the left 
medial lobe (2–3 animals/group). Inflammation and 
fibrosis were evaluated based on the morphology on the 
H&E stain, collagen deposition on a Picro Sirius stain 
and macrophage infiltration based on a CD68 immu-
nohistochemistry (IHC) stain. For the CD68 IHC stain, 
antigens were first retrieved by TEG buffer pH 9.0 and 
subsequently blocked with 0.5% hydrogen peroxide fol-
lowed by avidin and biotin (Invitrogen, CA, USA). The 
slides were then incubated with primary antibody (3 µg/
mL, MCA341R, AbD serotec, CA, USA) for 60  min, 
biotinylated secondary antibody for 60  min (1  µg/mL, 
715-065-151, Jackson ImmunoSearch, PA, USA) and 
ABC reagent (Vector Laboratories, CA, USA). Finally, 
macrophages were visualised with a DAB reagent (Dako, 
Glostrup, Denmark). All sections were scanned with 
a Hamamutsu slide scanner and later evaluated using 
NanoZoomer Digital Pathology Image software (Hama-
matsu, Hamamatsu City, Japan). The collagen and mac-
rophage areas were quantified by Visiomorph software 
(Visiopharm, Hoersholm, Denmark).
Inflammatory markers in tissues
As described above, livers, epididymal fat depots, and 
jejunal segments were excised from the animals immedi-
ately after sacrifice and stored at − 80  °C until analysis. 
Tissue protein concentrations of the three tissues were 
first determined using a Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, MA, USA) method accord-
ing to manufacturer’s instruction. TNF-α and MCP-1 
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levels were subsequently determined in tissue homogen-
ates with enzyme-linked immunosorbent assay (ELISA) 
kits (AB100785 and AB100778; Abcam, Cambridge, 
UK) according to manufacturer’s instructions. Absorb-
ance was read using a Spectramax 340PC384 microplate 
reader at 450 nm (Molecular Devices, CA, USA).
Statistical analysis
Statistical analyses were done using GraphPad Prism ver-
sion 6.05 (GraphPad Software Inc., La Jolla, CA, USA). 
Data were assumed to be normally distributed and con-
firmed by visual inspection of qq-plots. In case of severe 
deviations from normality, statistical analyses were per-
formed on log-transformed data (natural logarithm) or 
with the use of non-parametric tests. Data are presented 
as mean ± SEM, except for log-transformed data, which 
are presented as geometric means with 95% confidence 
intervals. Differences in means between diet groups for 
each parameter were analyzed using one-way ANOVA, 
repeated measures two-way ANOVA or Kruskal–Wallis 
tests where appropriate, and compared after 16 weeks on 
the diets. Bonferroni or Dunn corrections, respectively, 
were used to adjust for multiple comparisons. Outliers in 
data sets were identified and removed using the ROUT-
function in GraphPad Prism. p-values  <  0.05 were con-
sidered significant.
Results
Baseline characteristics for Control, HFD, HFr and 
NASH-groups are given in Table 2 and show that groups 
were comparable at study start for all parameters.
Effects of diet on body weight, energy intake and fat 
distribution
Figure  1 shows changes in body weight, fat mass and 
energy intake. Body weight increased throughout the 
study in all groups, but did not differ from Control after 
16  weeks (Fig.  1a). Fat mass was significantly increased 
in HFD-fed animals compared to both those fed Con-
trol and HFr-diets (p < 0.05, Fig. 1b) after 16 weeks. After 
8  weeks, accumulated energy intake was significantly 
higher in NASH-fed rats, compared to both Control- 
and HFr-fed rats (p < 0.001 and p < 0.05, Fig. 1c) and in 
HFD-fed rats compared to Control (p < 0.05). This differ-
ence remained significant only in NASH-fed compared to 
Control-fed rats after 16 weeks (p < 0.05).
Effects of diet on the liver
Throughout the study, liver density (used as an indirect 
measure of liver fat content) continuously declined in 
all four diet groups as measured by qCT with the effect 
being most pronounced in the NASH-group (Fig.  2a). 
At both 8 and 16  weeks, the decrease in liver density 
was significantly greater in NASH and HFD compared 
to Control (p < 0.0001 and p < 0.05) and in NASH com-
pared to HFD and HFr (p < 0.0001).
Livers from NASH-fed rats weighed significantly more 
compared to Control (p < 0.0001), HFD (p < 0.0001) and 
HFr (p < 0.001, Table 3), as did livers from HFr-fed rats 
compared to HFD (p  <  0.05). Hepatic TG content was 
higher in NASH- and HFD-fed rats compared to both 
Control (p < 0.01 and p < 0.0001) and HFr (p < 0.01 and 
p  <  0.0001, Fig.  2b). Additionally, HFD-fed animals had 
higher hepatic TG levels compared to NASH (p < 0.01). 
Hepatic TG levels in rats fed HFr did not differ from 
those fed the Control diet. Hepatic TC levels were signifi-
cantly elevated in NASH-fed animals compared to Con-
trol, HFD, and HFr (p < 0.0001, Fig. 2c). Liver glycogen 
was significantly lower in both NASH and HFD com-
pared to Control and HFr (p < 0.0001, Fig. 2d). At week 
16, ALAT-levels were significantly higher in NASH-fed 
rats compared to Control- (p  <  0.0001, Fig.  3a), HFD- 
and HFr-fed rats (p < 0.01). Plasma levels of ASAT were 
higher in the NASH-group compared to both Control- 
and HFr-groups (p < 0.05, Fig. 3b). Furthermore, plasma 
levels of the β-oxidation marker β-hydroxybuturate were 
increased in HFD-fed rats compared to Control-, NASH- 
and HFr-groups (p  <  0.0001, p  <  0.01 and p  <  0.0001, 
Table 3).
The histological evaluation is presented in Fig. 4. After 
16  weeks, hepatic steatosis was present in NASH, HFD 
and HFr-fed rats as confirmed by corresponding Oil Red 
O stains. No pathological changes were observed in liv-
ers of Control-fed rats. Steatosis was phenotypically dis-
tinguishable between NASH-, HFD- and HFr-fed rats. 
While zonal distribution was comparable (originating in 
Table 2 Baseline characteristics of rats immediately 
after randomization to either Control-, NASH-, HFD- or 
HFr-diets
Results are presented as mean ± SEM
HU Hounsfield units, TG triglycerides, FFA free fatty acids, HDL-C high-density-
lipoprotein-cholesterol, ALAT alanine aminotransferase, ASAT aspartate 
aminotransferase. Sample sizes: n = 10/group
Control NASH HFD HFr
Body weight (g) 454.9 ± 6.6 457.7 ± 5.7 442.7 ± 7.0 447.7 ± 8.8
Fat mass (g) 43.6 ± 2.6 44.4 ± 2.4 46.7 ± 2.0 44.9 ± 2.6
Liver density (HU) 40.0 ± 1.0 39.6 ± 0.6 40.7 ± 1.0 38.9 ± 0.8
Plasma TG (mM) 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.3 ± 0.2
Plasma FFA (mM) 0.3 ± 0.02 0.3 ± 0.03 0.4 ± 0.03 0.3 ± 0.02
Plasma cholesterol 
(mM)
1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 1.6 ± 0.1
Plasma HDL-C (mM) 1.0 ± 0.04 1.0 ± 0.1 1.1 ± 0.04 1.0 ± 0.1
ALAT (U/L) 33.0 ± 2.1 31.9 ± 1.7 35.7 ± 2.8 33.1 ± 1.9
ASAT (U/L) 62.4 ± 1.9 59.9 ± 3.5 61.5 ± 2.9 63.2 ± 2.3
Page 5 of 13Jensen et al. Diabetol Metab Syndr  (2018) 10:4 
zone 1, periportally), steatosis in HFD-rats was almost 
exclusively found to be of the microvesicular type; in 
HFr-fed rats almost exclusively macrovesicular; while the 
NASH-fed rats represented an intermediate between the 
two, with both macro- and microvesicular steatosis. Fur-
thermore, steatosis in the NASH-group at week 16 was 
much more pronounced, involving not only zone 1, but 
occasionally also zones 2 and 3 and in some animals, only 
few areas displayed normal liver architecture. Inflamma-
tory hepatic infiltration was identified in both NASH-, 
HFD- and HFr-fed rats. In all three groups, inflammation 
was characterized by being of primarily mononuclear 
composition with occasional neutrophilic involvement. 
However in HFr-fed rats, inflammatory cells appeared to 
center around lipid-loaded hepatocytes and form struc-
tures resembling lipogranulomas, whereas inflamma-
tory infiltrates observed in HFD-fed rats were randomly 
scattered and not consistently associated with steato-
sis. As with the steatosis, inflammatory changes in the 
NASH-group were more pronounced, as exemplified by 
larger and more disseminated infiltrates. Accordingly, 
hepatic macrophage numbers were two- to threefold 
increased in the NASH-group compared to Control- and 
HFD-fed rats (p < 0.001 and p < 0.01, Fig. 5a, b). Hepatic 
deposition levels of collagen was higher in NASH-
animals than in other groups, albeit only significantly 
increased compared to HFD (p < 0.001, Fig. 5c, d).
Effects of diet on plasma lipids and general metabolic state
Plasma FFA did not differ between groups (Table  3). 
HFr-feeding induced a significant increase in circu-
lating TG, compared to Control-, NASH- and HFD 
(p  <  0.0001, Table  3). Plasma HDL-c levels were simi-
lar between groups, as were the plasma cholesterol lev-
els (Table  3). Fasting hyperglycemia was present in all 
groups compared to Control after 16 weeks (NASH and 
HFr: p < 0.01, HFD: p < 0.0001, Table 3). However, fast-
ing plasma insulin levels did not differ between groups 
Fig. 1 Effects on body weight, fat mass and energy intake of Control-, NASH-, HFD- and HFr-diets. a Body weight increased in all 4 diet groups 
throughout the study, but did not differ after 16 weeks. b After 8 weeks fat mass was significantly increased in HFD-fed rats compared to Con-
trol- and HFr-fed rats. This effect was still present at week 16. c After 8 weeks, accumulated energy intake was significantly higher in NASH-fed rats, 
compared to both Control- and HFr-fed rats and in HFD-fed rats compared to Control. This remained significant only in NASH-fed compared to 
Control-fed rats after 16 weeks. Comparisons between groups: *NASH vs. Control; #NASH vs. HFr; †HFD vs. Control. Statistical significance: *p < 0.05; 
***p < 0.001; #p < 0.05; ##p < 0.01; †p < 0.05
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(Table  3). Circulating leptin levels were significantly 
increased in the HFD-fed rats compared to both Control- 
(p < 0.05), NASH- (p < 0.05) and HFr-fed rats (p < 0.01, 
Table 3).
Effects of diet on markers of systemic and tissue‑specific 
inflammation
Hepatic levels of MCP-1 were significantly increased in 
rats on NASH (p < 0.01), HFD diet (p < 0.0001) and HFr 
diet (p < 0.01) compared to Control (Fig. 3c). Additionally, 
hepatic TNF-α levels were higher in HFD fed rats com-
pared to Control- (p < 0.001), NASH (p < 0.0001) and HFr 
(p < 0.01, Fig. 3d). Haptoglobin was significantly increased 
in plasma of NASH-fed rats compared to rats fed Con-
trol (p  <  0.001), HFD (p  <  0.0001) and HFr (p  <  0.001, 
Fig.  3e). Concentrations of MCP-1 and TNF-alpha were 
not elevated in adipose or intestinal tissue in any of the 
diet-groups compared to Control; however, HFr-fed rats 
had significantly higher levels of adipose tissue MCP-1 
compared to both NASH- and HFD-fed rats (p  <  0.05, 
Table 3). MCP-1 was below detection limit in plasma in all 
groups. Plasma TIMP-1 levels was significantly increased 
in the NASH-fed rats, compared to all other groups (vs. 
Control: p < 0.01; vs. HFD and HFr: p < 0.001, Fig. 3f ).
Fig. 2 Effects on liver in Control-, NASH-, HFD- and HFr-fed rats. a Throughout the study, liver density continuously declined in all four diet groups, 
with the effect being more pronounced in the NASH-group. Both halfway through the study period and at the week 16 time point the decline in 
liver density was significantly greater in NASH and HFD compared to Control and in NASH compared to HFD and HFr. b Liver triglyceride content 
was significantly elevated in NASH- and HFD-fed rats compared to Control and HFr. Additionally, HFD-fed rats had significantly higher hepatic TG 
levels compared to NASH-fed. Hepatic TG levels in rats fed HFr did not differ from those fed the Control-diet. c Hepatic cholesterol levels were sig-
nificantly elevated in NASH-fed animals compared to Control, HFD, and HFr. d The level of liver glycogen was significantly lower in both NASH and 
HFD compared to Control and HFr. a Comparisons between groups: *Control vs. NASH; †Control vs. HFD; ¤NASH vs. HFD; #NASH vs. HFr. Statistical 
significance: ****p < 0.0001; †p < 0.05; ¤¤¤¤p < 0.0001; ####p < 0.0001. b–d. Statistical significance: **p < 0.01; ****p < 0.0001. TG triglyceride, TC total 
cholesterol, NASH NASH-diet, HFD high-fat diet, HFr high fructose diet. Results are shown as mean ± SEM
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Discussion
The present study shows that feeding rats diets high in 
either dietary fat or dietary fructose results in distinctly 
different hepatic, metabolic and inflammatory profiles in 
rats. When comparing the effect of dietary fat and fruc-
tose, high-fat feeding more potently induce development 
of fatty liver and associated hepatic inflammation without 
affecting the circulating lipid pool. In contrast, high-fruc-
tose feeding appear to have the most pronounced effects 
on the plasma lipid profile, while only subtle effects on 
the liver are observed. The combination of fat, fructose, 
and cholesterol exacerbated and intensified overall effects 
on the liver. The strength of this study is the direct com-
parison of dietary fat (with very restricted amounts of 
carbohydrate) and dietary fructose (with very restricted 
amounts of fat) on parameters associated with NAFLD. 
This enables a more detailed evaluation of the individual 
roles of these macronutrients in disease progression. Fur-
thermore, the use of qCT allows the non-invasive assess-
ment of NAFLD-progression throughout the study, a 
method which to our knowledge has not previously been 
applied in rat studies comparing NAFLD progression 
after administration of different diets.
NAFLD in humans is often associated with obesity and 
insulin resistance, and these metabolic derangements 
were more closely reflected in the HFD-group. Accord-
ingly, only HFD-fed rats became obese and even though 
the cumulative energy intake in this group was transiently 
higher than Control animals at week 8, differences in 
energy intake did no longer account for the HFD-induced 
obesity after 16  weeks. Circulating leptin levels were 
also significantly elevated only in HFD-fed rats, reflect-
ing the increase in adipose tissue depot size within this 
group. Fasting hyperglycemia was present in all groups 
at study termination, indicating disturbances in glucose 
metabolism, even though fasting insulin levels remained 
similar between groups. These disturbances were further 
corroborated by the increased levels of hepatic TG and 
decreased/unaltered hepatic glycogen observed in both 
NASH-, HFD- and HFr-fed rats, indicative of selective 
insulin resistance [23].
Hepatic steatosis was rapidly induced in both NASH- 
and HFD-fed rats and was shown using qCT to progress 
in a time-dependent manner. In line with this, higher 
levels of plasma β-hydroxybutyrate were observed in 
HFD-fed rats, suggestive of increased β-oxidation due 
to hepatic lipid overload. The role of hepatic β-oxidation 
in the pathogenesis of NAFLD remains controversial, 
but several studies in human NASH-patients have found 
serum levels of β-hydroxybutyrate to be increased [24, 
25]. Although not significant, there was a trend towards 
an increase of this marker in NASH-fed rats as well. The 
development of hepatic steatosis in NASH- and HFD-fed 
rats agrees well with recent studies in other rodent spe-
cies suggesting fat and cholesterol to be important driv-
ers in the development of experimental NAFLD/NASH 
[14, 22]. The addition of dietary cholesterol (NASH-diet) 
caused the most detrimental liver changes, evident by 
significant accumulation of both hepatic TG and choles-
terol, pronounced decreases in liver density, and severe 
morphological alterations in liver histology. In contrast 
to what was observed in HFD- and HFr-fed rats, these 
Table 3 Metabolic and inflammatory effects in rats after 16 weeks on NASH-, HFD- and HFr-diet
TG triglycerides, FFA free fatty acids, HDL-C high-density-lipoprotein-cholesterol, MCP-1 monocyte-chemoattractant-protein-1, TNF-α tissue-necrosis-factor-alpha
Results are presented as mean ± SEM. Metabolic parameters denoted with superscript a, were analysed on log-transformed data (due to non-normal distribution), and 
are consequently presented as geometric means with 95% confidence intervals. Superscripts (*,#,†,‡) indicate significant (p < 0.05) differences in readouts compared to 
Control-, NASH-, HFD- and HFr-groups respectively. Sample sizes at week 16: n = 6–10/group. b Fasting plasma glucose and fasting plasma insulin levels were assessed 
after 15 weeks
Control NASH HFD HFr
Liver weight (g) 18.9 ± 3.4# 32.7 ± 7.9*†‡ 16.5 ± 2.5# ‡ 23.1 ± 4.4#†
Fasting plasma glucose (mM)b 6.4 ± 0.2#†‡ 7.2 ± 0.2* 7.5 ± 0.1* 7.16 ± 0.2*
Fasting plasma insulin (pM)b 560.6 ± 79.5 486.7 ± 93.7 603.0 ± 43.7 695.8 ± 83.7
Plasma β-hydroxybutyrate (µmol/L) 38.4 ± 4.2† 64.0 ± 5.3† 115.4 ± 16.8*#‡ 38.4 ± 2.8†
Plasma leptin (ng/mL) 3283.3 ± 1035.2† 3803.0 ± 1341.1† 9366.6 ± 2052.8*#‡ 2638.0 ± 808.5†
Plasma TG (mmol/L) 1.6 ± 0.2‡ 1.7 ± 0.1‡ 1.5 ± 0.1‡ 3.9 ± 0.5*#†
Plasma FFA (mmol/L) 0.3 ± 0.1 0.4 ± 0.03 0.4 ± 0.02 0.3 ± 0.02
Plasma Cholesterol (mmol/L) 2.1 ± 0.1 2.5 ± 0.1 2.1 ± 0.1 2.3 ± 0.2
Plasma HDL-C (mmol/L) 1.3 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 1.1 ± 0.1
Jejunal MCP-1 (ng/mL)a 45.3 [36.3; 55.3] 58.1 [48.5; 69.6] 49.5 [40.1; 60.5] 56.4 [48.1; 65.5]
Jejunal TNF-α (ng/mL)a 179.9 [129.3; 247.7] 87.6 [61.7; 125.5] 171.1 [76.1; 384.6] 213.2 [112.4; 404.3]
Adipose tissue MCP-1 (ng/mL)a 14.8 [13.4; 16.5] 14.1 [11.9; 16.8]‡ 14.2 [11.3; 17.7]‡ 25.6 [15.2; 42.6]#†
Adipose tissue TNF-α (ng/mL)a 15.4 [14.4; 16.4] 16.1 [14.3; 18.2] 15.4 [13.6; 18.2] 16.2 [14.6; 18.0]
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Fig. 3 Markers of hepatic function, inflammation and fibrosis. a After 16 weeks ALAT-levels were significantly higher in NASH-fed rats compared to 
Control-, HFD- and HFr-fed rats. b Plasma levels of ASAT were higher in the NASH-group compared to both Control and HFr-groups. c Rats on NASH, 
HFD and HFr-diet had increased hepatic levels of MCP-1 compared to Control. d Hepatic TNF-α levels were significantly increased in the HFD fed 
rats compared to Control. e Haptoglobin was significantly increased in plasma of NASH-fed rats compared to rats fed Control, HFD and HFr. f Plasma 
TIMP-1 was significantly increased in the NASH-fed rats, compared to all other groups. Statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001. Results are shown as mean ± SEM
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changes were also accompanied by increased plasma lev-
els of ALAT and ASAT, suggesting impaired liver func-
tion. It has previously been observed in both mice [26, 
27] and humans [28] that the combined intake of dietary 
fat and carbohydrates, or of fat and cholesterol [29] can 
result in accelerated and more severe effects in the liver. 
The majority of these changes could be driven by the 
amount of cholesterol in the NASH-diet (2%), as hepatic 
levels of cholesterol measured in NASH-fed rats were 
very high. Supporting this, two previous studies in mice 
have suggested that dietary cholesterol is important in 
facilitating progression from simple steatosis to NASH 
[30] and that free cholesterol loading can sensitize the 
liver to cytokine-mediated hepatocellular death, inflam-
mation and oxidative stress [31]. This could account for 
the more aggravated inflammatory histological response, 
supported by the significant increase in infiltrating mac-
rophages observed in livers of NASH-fed rats compared 
to both HFD and Control groups. Further studies are 
needed to determine if these changes are caused exclu-
sively by the cholesterol content, by a synergistic effect of 
fat and fructose, or by a combination of all.
While fat and cholesterol both seem to contribute to 
the development of NAFLD, previous studies in rats have 
shown that also high levels of dietary fructose are capable 
of inducing hepatic steatosis, inflammation and increase 
oxidative stress markers within a relatively short time-
span of only 2–5  weeks [32–34]. These are in contrast 
to our findings with the HFr-diet, which only induced 
subtle changes in the liver. While steatosis was observed 
Fig. 4 Histological evaluation of liver sections from Control-, NASH-, HFD- and HFr-fed rats. Row 1: representative H&E-stains of normal liver from 
a Control-fed rat, and hepatic steatosis in b NASH-fed rat, c HFD-fed rat and d HFr-fed rat. Hepatic steatosis in HFD-fed rats was almost exclusively 
found to be microvesicular (c); in HFr-fed rats almost exclusively macrovesicular (d); while steatosis in NASH-fed rats represented an intermediate 
between the two, with both macro- and microvesicular steatosis (b). Row 2: higher magnification of representative H&E stained liver sections. e 
Liver morphology appeared normal in Control-fed rats, whereas inflammatory infiltrates were observed in livers from f NASH-fed rats, g HFD-fed 
rats and h HFr-fed rats Row 3: Oil Red O stains of liver sections from j NASH-fed rats, k HFD-fed rats and l HFr-fed rats confirmed hepatic steatosis 
observed in b–d. i Oil Red O staining of liver from Control-fed rat
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histologically in some animals in the HFr-group the con-
dition was not confirmed by increased levels of liver TG 
at the week 16 time point. The apparent discrepancy 
between histological and biochemical analyses within 
the HFr-group could result from sampling variation, a 
problem also commonly encountered in biopsy-guided 
diagnosis of human NAFLD/NASH [35]. Biochemical 
analyses of hepatic TG-content was performed on liver 
tissue sampled from the left lateral lobe and histologic 
evaluation of livers in the HFr-group (performed on both 
left lateral, right medial and the caudate lobe) did in fact, 
in some animals, show specific lobes to be more severely 
affected than others, indicating that steatosis, at least 
in rats fed fructose-enriched diets, may not be homog-
enously distributed throughout the liver. Further studies, 
confirming the heterogeneously distributed steatosis 
would be interesting in terms of evaluating and compar-
ing histology, biochemistry and imaging of the liver in 
rodent models of NAFLD/NASH.
Dyslipidemia is one of the hallmarks of the metabolic 
syndrome and has been shown to be strongly associated 
with NAFLD [36]. Dyslipidemia associated with NAFLD 
is typically characterized by elevated levels of circulat-
ing TG and low-density-lipoprotein cholesterol (LDL-
C), as well as decreased HDL-C levels [37]. Only rats 
fed HFr-diet developed dyslipidemia, as defined by the 
presence of hypertriglyceridemia. Previous studies have 
also found that dietary fructose potently increase TG in 
plasma within a relatively short timeframe in both rats 
and mice [34, 38]. In rats, this has been suggested to be 
Fig. 5 Macrophage infiltration and collagen deposition. A significant increase in macrophage infiltration was seen in NASH-fed rats, compared 
to Control- and HFD.fed rats (a) and collagen deposition in NASH-fed rats trended towards being increased, although only significantly when 
compared to HFD-rats (b). Representative CD68- (c) and Picro Weigert-stains (d) of liver from NASH-fed rat. Statistical significance: **p < 0.01; 
***p < 0.001. Results in a and c are shown as mean ± SEM
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caused in part by the ability of fructose to both increase 
hepatic very-low-density-lipoprotein (VLDL)-TG secre-
tion and decrease VLDL-TG clearance from the circula-
tion, even in the absence of hyperinsulinemia [39, 40]. 
Mechanistically, the increase in VLDL-TG secretion has 
been proposed to result from a combined effect of fruc-
tose-induced hepatic stress responses [40], and activation 
of hepatic enzymes involved in the de novo synthesis of 
fatty acids (de novo lipogenesis) [41].
In contrast to the HFr-diet, neither the HFD- nor 
the NASH-diet resulted in increased plasma TG, even 
though high-fat diets have previously been shown to 
induce hypertriglyceridemia in rats [42]. However, our 
findings agree with a recent study in mice investigat-
ing the contribution of dietary fat and cholesterol to 
NAFLD-development, which showed no effect of dietary 
fat and cholesterol on circulating TG or FFA levels, inde-
pendently of whether these macronutrients were fed sep-
arately or in combination [29]. One explanation could be 
that accelerated fat accumulation in the liver imposes a 
significant strain on metabolic pathways responsible for 
the release of lipids from the liver into plasma. Accord-
ingly, it has been shown both in vitro and in vivo that high 
levels of fat and cholesterol in the liver result in increased 
stress in the endoplasmic reticulum, limiting secre-
tion of apolipoprotein B100 (an essential component in 
the assembly of VLDL-particles) and thereby inhibits 
hepatic export of TG [29, 43]. The inflammatory profile 
was clearly distinguishable between groups in the present 
study. Systemic inflammation was present only in NASH-
fed rats with higher circulating levels of haptoglobin. 
We also found increased levels of the pro-inflammatory 
cytokines MCP-1 and TNF-alpha in liver tissue homoge-
nates in NASH-, HFD- and HFr- and in HFD-fed rats, 
respectively, suggesting progression of hepatic steatosis 
towards NASH with the increased inability of the liver 
to cope with fat infiltration. The inflammatory infiltrates 
observed histologically in livers of HFr- and NASH-fed 
rats at week 16, were reflected only in significantly higher 
levels of hepatic MCP-1, not TNF-alpha. Compared to 
the other diet-groups, NASH-fed rats might be expected 
to have the highest levels of liver inflammatory cytokines, 
due to the higher macrophage count, increased liver 
enzymes, and the more severe liver pathology. However, 
hepatic macrophages are a remarkably heterogeneous 
population of immune cells, whose effector function 
depends on origin, underlying pathogenesis and disease 
stage, which can result in high diversity in inflammatory 
cytokines released and cell surface markers [44, 45]. This 
could explain why the NASH-fed group does not have 
the highest hepatic MCP-1 and TNF-alpha levels despite 
the higher macrophage count and the more severe liver 
pathology. Despite increased hepatic MCP-1 levels in all 
groups compared to Control, MCP-1 plasma levels were 
below detection limit.
It has been hypothesized that fructose and fat may 
induce their inflammatory action in the liver not only 
by dietary overload, but also by stimulation of bacterial 
overgrowth in the intestine, increasing intestinal perme-
ability and thereby facilitating translocation of endotox-
ins across the intestinal barrier that are then transported 
to the liver [46, 47]. In the present study, we were not 
able to detect increased intestinal levels of TNF-alpha 
or MCP-1 in any diet group. Moreover, we did not find 
increased levels of MCP-1 and TNF-alpha in visceral 
adipose tissue in any of the groups, even though inflam-
mation particularly in the adipose tissue compartment 
is strongly associated with NAFLD/NASH in humans 
[48]. Notably, the cytokine analyses in this study were 
performed on epididymal fat depots, which may not 
adequately represent visceral adipose tissue depots in 
humans [49].
Although fibrosis is not a prerequisite for the NASH 
diagnosis, it often accompanies the three recognized 
diagnostic hallmarks (steatosis, lobular inflammation 
and hepatocyte ballooning), and can be used as a grading 
tool for evaluation of NASH severity [50]. In the present 
study, neither cellular ballooning nor fibrosis was present 
in any of the groups. However, increased levels of plasma 
haptoglobin and TIMP-1 were observed in NASH-fed 
rats and are considered predictors of these pathological 
liver changes, indicating that the NASH diet might be 
promising in terms of modelling more advanced stages 
of NASH within a relatively short time-frame. The ten-
dency towards increased collagen deposition in NASH-
fed rats further supports this. The inability of the diets 
used in this study to induce liver fibrosis in rats after only 
16  weeks is not entirely surprising. Successful dietary 
induction of fibrosis in rodent models of NASH has so 
far mainly been associated with either genetic manipula-
tion, forced overfeeding or diets low in methionine and 
choline, [51, 52], except for the guinea pig that has been 
shown to develop NASH after 16 weeks of high fat feed-
ing [22]. However, mild hepatic fibrosis in addition to a 
NASH-like phenotype has also been induced in C57BL/6 
mice on a high-fat diet, but only after 50 weeks [53]. In 
a recent study, using levels of dietary cholesterol compa-
rable to the level in the NASH-diet in our study, devel-
opment of fibrosis in Sprague–Dawley rats was observed 
after only 9  weeks. [54]. However, the diets used by 
Ichimura and colleagues included relatively high levels of 
dietary cholate (2%), which is known to potently induce 
hepatotoxicity and upregulate specific genes related to 
hepatic fibrosis [55].
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Conclusion
Dietary fat seems to primarily drive NAFLD development 
in Sprague–Dawley rats with potent effects on hepatic 
fat accumulation and inflammation, whereas dietary 
fructose primarily affects circulating lipids with much 
more subtle effects on the liver. Combining fat, fructose 
and cholesterol accelerates NAFLD development and 
increase the overall severity of changes observed in the 
liver.
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